Read + Share
Wu X, Qu F, Hua Y, Lu R, et al. An open-label phase II study: The efficiency and safety of anlotinib + eribulin
in patients with HER2-negative metastatic breast cancer. Int J Cancer 2025 Aug 11. doi: 10.1002/ijc.70079.
PMID: 40788158
|
 |
|
Wu X, Qu F, Hua Y, Lu R, et al. An open-label phase II study: The efficiency and safety of anlotinib + eribulin
in patients with HER2-negative metastatic breast cancer. Int J Cancer 2025 Aug 11. doi: 10.1002/ijc.70079.
PMID: 40788158
|
|
|
|